CA125 is the gold standard tumor marker in ovarian cancer. Serum level of CA125 is used to
monitor response to chemotherapy, relapse, and disease progression in ovarian cancer …

Epithelial ovarian cancer is the leading cause of death among gynecologic malignancies.
Treatment of recurrent ovarian cancer remains a challenge despite advances in surgical and …

Objective The first-line chemotherapy for ovarian cancer is based on a combination of
platinum and taxane. To date, no reliable predictive biomarker has been recognized that is …

Ovarian cancer is frequently diagnosed at an advanced stage and a fraction of these
patients fail to respond to primary therapy and relapses in 70% of cases. On account of the …

Background: CA 125 assays enable treatment-response monitoring in ovarian cancer.
Patients and methods: A multicentric study of CA 125 kinetics under induction chemotherapy …

Newly diagnosed high grade serous epithelial ovarian cancer (EOC) patients are treated
with radical surgery followed by adjuvant platinum and taxane combination chemotherapy …

Tumour stage, residual disease after initial surgery, histological type and tumour grade are
the most important clinical-pathological factors related to the clinical outcome of patients with …

Purpose: To discover and validate serum glycoprotein biomarkers in ovarian cancer using
proteomic-based approaches. Experimental Design: Serum samples from a “discovery set” …

OBJECTIVE: To evaluate the predictive power of serum CA-125 changes in the
management of patients undergoing neoadjuvant chemotherapy followed by interval …

Prognostic markers may potentially help to individualize treatment within subgroups of
patients. In a recent study the level of cancer antigen 125 expression was consistently found …